NFA
OMED

Nationwide Fund Advisors’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Nationwide Fund Advisors’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-12,831
Closed -$118K – 3368
2017
Q1 		$118K Sell
12,831
-1,432
-10% -$12.6K ﹤0.01% 2794
2016
Q4 		$110K Buy
14,263
+1,070
+8% +$9.83K ﹤0.01% 2845
2016
Q3 		$151K Sell
13,193
-20,009
-60% -$233K ﹤0.01% 2763
2016
Q2 		$409K Sell
33,202
-367
-1% -$4.45K ﹤0.01% 2248
2016
Q1 		$339K Sell
33,569
-1,115
-3% -$13.1K ﹤0.01% 2291
2015
Q4 		$782K Buy
34,684
+6
+0% +$123 ﹤0.01% 1851
2015
Q3 		$575K Buy
34,678
+23,745
+217% +$476K ﹤0.01% 2027
2015
Q2 		$246K Buy
10,933
+1,640
+18% +$40.4K ﹤0.01% 2596
2015
Q1 		$240K Sell
9,293
-297
-3% -$7.53K ﹤0.01% 2605
2014
Q4 		$209K Sell
9,590
-134
-1% -$2.75K ﹤0.01% 2613
2014
Q3 		$184K Buy
9,724
+113
+1% +$2.27K ﹤0.01% 2737
2014
Q2 		$224K Buy
9,611
+5,991
+165% +$148K ﹤0.01% 2696
2014
Q1 		$122K Hold
3,620
– – ﹤0.01% 2686
2013
Q4 		$107K Sell
3,620
-4,432
-55% -$81.2K ﹤0.01% 2934
2013
Q3 		$123K Buy
+8,052
New +$149K ﹤0.01% 2876

Other funds holding OMED

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
IHM
Iguana Healthcare Management New York $152M AUM 48.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Nationwide Fund Advisors's OMED Position: Q2 2017 in Review

Nationwide Fund Advisors sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2017, closing a stake of 12,831 shares — an estimated $118K sold.

Nationwide Fund Advisors first reported a position in OMED in Q3 2013 and held it in 15 quarters. The position peaked at $782K in Q4 2015. 68 funds tracked by Wall St. Rank hold OMED as of Q2 2017.

  • Nationwide Fund Advisors reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 12,831 OncoMed Pharmaceuticals, Inc. shares in Q2 2017, an estimated $118K.
  • Nationwide Fund Advisors first reported a position in OncoMed Pharmaceuticals, Inc. in Q3 2013 and held it in 15 quarters.
  • Nationwide Fund Advisors's OncoMed Pharmaceuticals, Inc. position peaked at $782K in Q4 2015.
  • 68 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2017.

Based on Nationwide Fund Advisors's 13F filing for Q2 2017, filed 10 Aug 2017.